UroGen Pharma Ltd. (URGN)Healthcare | Biotechnology | Princeton, United States | NasdaqGM
29.72 USD
+0.22
(0.746%)
⇧
(June 12, 2026, 4 p.m.
EDT)
After hours: 29.56 -0.16 (-0.160%) ⇩ (June 12, 2026, 7:34 p.m. EDT) |
Hot Take ↕ | June 7, 2026, 4:50 a.m. EDT
The investment case here is fraught with tension between aggressive analyst targets and deteriorating operational reality. While the forward P/E of 22 and a 'strong buy' consensus suggest the market is pricing in a turnaround, the company is currently burning cash at an alarming rate, with operating cash flow at -$165 million and free cash flow at -$109 million. Revenue growth of 151% is impressive but likely reflects a base effect or a specific product launch rather than sustainable profitability, given the massive losses. The balance sheet is precarious, with debt exceeding cash reserves, forcing reliance on capital markets or dilution. The price action tells a story of a speculative trap. The stock has been volatile, trading well below its 52-week high, yet the recent 100% rally mentioned in headlines suggests a short squeeze or a catalyst-driven spike rather than organic accumulation. The options data confirms this: traders are buying deep OTM puts as insurance, while call activity is scattered. This is not a fortress balance sheet or a dominant competitive moat; it is a high-risk biotech play dependent on the successful commercialization of a single asset class. Until the company demonstrates a path to breakeven and reduces its burn rate, the 'gem' narrative is outweighed by the risk of insolvency or further dilution. The long-term rating is capped because the multi-year trajectory shows significant erosion, and the current fundamentals do not yet support a 'buy and hold' thesis despite the optimistic analyst targets. |
| Model | MAE |
|---|---|
| MSTL_115 ✓ | 0.188710 |
| AutoTheta | 0.227545 |
| AutoETS | 0.227682 |
| AutoARIMA | 0.228543 |
| MSTL_70_115 | 0.241470 |
| MSTL | 0.250949 |
| MSTL_70 | 0.319892 |
Forecast horizon: 60 days | Selected: MSTL_115
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 41.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.131 |
| Excess Kurtosis | -1.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.879 |
| Market Cap | 1,448,008,832 |
| Forward P/E | 24.19 |
| Beta | 1.62 |
| Profit Margins | -94.83% |
| Website | https://www.urogen.com |
As of June 7, 2026, 4:50 a.m. EDT: Speculators are positioning for volatility rather than a clear directional breakout. Call volume is concentrated near the money (27-28 strikes) with significant open interest walls further out (33-34), suggesting a desire for upside participation without immediate commitment. However, put open interest is heavily skewed toward deep out-of-the-money strikes (15-18) for August expiration, indicating a hedge against a significant drop or a 'long gamma' setup where dealers face limited downside risk. The lack of volume in July puts suggests the market is not pricing in an imminent crash, but the deep OTM put positioning acts as a floor for a potential correction.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0725243 |
| Address1 | 400 Alexander Park Drive |
| Address2 | 4th Floor |
| All Time High | 69.568 |
| All Time Low | 3.42 |
| Ask | 37.72 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 658,440 |
| Average Daily Volume3 Month | 795,396 |
| Average Volume | 795,396 |
| Average Volume10Days | 658,440 |
| Beta | 1.623 |
| Bid | 22.22 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | -2.551 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 29.72 |
| Current Ratio | 4.69 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,780,012,800 |
| Day High | 31.285 |
| Day Low | 29.32 |
| Display Name | UroGen Pharma |
| Earnings Call Timestamp End | 1,778,076,000 |
| Earnings Call Timestamp Start | 1,778,076,000 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -107,902,000 |
| Ebitda Margins | -0.76802003 |
| Enterprise To Ebitda | -13.946 |
| Enterprise To Revenue | 10.711 |
| Enterprise Value | 1,504,827,904 |
| Eps Current Year | -0.905 |
| Eps Forward | 1.22875 |
| Eps Trailing Twelve Months | -2.74 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 25.6938 |
| Fifty Day Average Change | 4.0261993 |
| Fifty Day Average Change Percent | 0.15669926 |
| Fifty Two Week Change Percent | 107.25243 |
| Fifty Two Week High | 32.37 |
| Fifty Two Week High Change | -2.6499996 |
| Fifty Two Week High Change Percent | -0.081865914 |
| Fifty Two Week Low | 12.61 |
| Fifty Two Week Low Change | 17.11 |
| Fifty Two Week Low Change Percent | 1.3568597 |
| Fifty Two Week Range | 12.61 - 32.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,904,600,000 |
| Float Shares | 43,174,735 |
| Forward Eps | 1.22875 |
| Forward P E | 24.187181 |
| Free Cashflow | -109,282,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 298 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,780,531,200 |
| Gross Margins | 0.89852995 |
| Gross Profits | 126,237,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.036459997 |
| Held Percent Institutions | 1.00588 |
| Implied Shares Outstanding | 48,721,701 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey. |
| Long Name | UroGen Pharma Ltd. |
| Market | us_market |
| Market Cap | 1,448,008,832 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_240702165 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -133,225,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,448,008,953 |
| Number Of Analyst Opinions | 8 |
| Open | 29.48 |
| Operating Cashflow | -165,736,000 |
| Operating Margins | -0.39763 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 646 768 9780 |
| Post Market Change | -0.15999985 |
| Post Market Change Percent | -0.5383575 |
| Post Market Price | 29.56 |
| Post Market Time | 1,781,307,263 |
| Previous Close | 29.5 |
| Price Eps Current Year | -32.83978 |
| Price Hint | 2 |
| Price To Book | -11.650332 |
| Price To Sales Trailing12 Months | 10.306626 |
| Profit Margins | -0.94827 |
| Quick Ratio | 3.865 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | 0.219999 |
| Regular Market Change Percent | 0.74576 |
| Regular Market Day High | 31.285 |
| Regular Market Day Low | 29.32 |
| Regular Market Day Range | 29.32 - 31.285 |
| Regular Market Open | 29.48 |
| Regular Market Previous Close | 29.5 |
| Regular Market Price | 29.72 |
| Regular Market Time | 1,781,294,400 |
| Regular Market Volume | 584,457 |
| Return On Assets | -0.26982 |
| Revenue Growth | 1.516 |
| Revenue Per Share | 2.879 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 48,721,701 |
| Shares Percent Shares Out | 0.1421 |
| Shares Short | 6,921,016 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 7,236,438 |
| Short Name | UroGen Pharma Ltd. |
| Short Percent Of Float | 0.1449 |
| Short Ratio | 7.76 |
| Source Interval | 15 |
| State | NJ |
| Symbol | URGN |
| Target High Price | 45.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 36.875 |
| Target Median Price | 40.0 |
| Total Cash | 140,274,000 |
| Total Cash Per Share | 2.879 |
| Total Debt | 197,092,992 |
| Total Revenue | 140,492,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.8429 |
| Two Hundred Day Average Change | 7.8771 |
| Two Hundred Day Average Change Percent | 0.3606252 |
| Type Disp | Equity |
| Volume | 584,457 |
| Website | https://www.urogen.com |
| Zip | 8,540 |